Evidence map›Paper›PMID 38735640›Full record

ArticleOphthalmology. Retina2024

Isolated Retinal Neovascularization in Retinopathy of Prematurity: Clinical Associations and Prognostic Implications.

Spencer S Burt, Mani Woodward, Shuibin Ni, John Jackson, Aaron S Coyner, Susan R Ostmo, Guangru Liang, Yakub Bayhaqi, Yali Jia, David Huang and 4 more

Abstract read
In one paragraph

Article in Ophthalmology. Retina, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Spencer S BurtCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Mani WoodwardCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Shuibin NiCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
John JacksonCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Aaron S CoynerCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Susan R OstmoCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Guangru LiangCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Yakub BayhaqiCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Yali JiaCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
David HuangCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Michael F ChiangNational Eye Institute, National Institutes of Health, Bethesda, Maryland; National Library of Medicine, National Institutes of Health, Bethesda, Maryland.
Benjamin K YoungCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
Yifan JianCasey Eye Institute, Oregon Health and Science University, Portland, Oregon.
J Peter CampbellCasey Eye Institute, Oregon Health and Science University, Portland, Oregon. Electronic address: johnpetercampbell@gmail.com.

Funding

Proteomics CoreP30EY010572 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Kate E Keller · 1995 to 2026
$19.4M
Clinical and Genetic Analysis of Retinopathy of PrematurityR01EY019474 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CAMPBELL, JOHN PETER · 2010 to 2020
$7.0M
Artificial Intelligence Assisted Panoramic Optical Coherence Tomography Angiography for Retinopathy of PrematurityR01HD107494 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI John Peter Campbell, Yifan Jian · 2021 to 2026
$2.4M
Validation of artificial intelligence (AI) based software as medical device (SaMD) for retinopathy of prematurity (ROP)R44EY035596 · NEI · SILOAM VISION, INC. · PI CAMPBELL, JOHN PETER, JONAS, KARYN · 2023 to 2024
$2.0M
Clinical and genetic analysis of retinopathy of prematurityR01HD107493 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI CAMPBELL, JOHN PETER · 2021 to 2023
$1.8M
Artificial intelligence assisted panoramic Optical Coherence Tomography Angiography for Retinopathy of PrematurityR01EY031331 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CAMPBELL, JOHN PETER, JIAN, YIFAN · 2020 to 2020
$342k
NEI NIH HHS P30 EY010572NEI NIH HHS R01 EY019474NEI NIH HHS R01 EY031331NEI NIH HHS R44 EY035596NICHD NIH HHS R01 HD107493NICHD NIH HHS R01 HD107494
6 · The paper itself

Abstract

objectiveIsolated retinal neovascularization (IRNV) is a common finding in patients with stage 2 and 3 retinopathy of prematurity (ROP). This study aimed to further classify the clinical course and significance of these lesions (previously described as "popcorn" based on clinical appearance) in patients with ROP as visualized with ultrawidefield OCT (UWF-OCT).

designSingle center, retrospective case series.

participantsImages were collected from 136 babies in the Oregon Health and Science University neonatal intensive care unit.

methodsA prototype UWF-OCT device captured en face scans (>140°), which were reviewed for the presence of IRNV along with standard zone, stage, and plus classification. In a cross-sectional analysis we compared demographics and the clinical course of eyes with and without IRNV. Longitudinally, we compared ROP severity using a clinician-assigned vascular severity score (VSS) and compared the risk of progression among eyes with and without IRNV using multivariable logistic regression.

main outcome measuresDifferences in clinical demographics and disease progression between patients with and without IRNV.

resultsOf the 136 patients, 60 developed stage 2 or worse ROP during their disease course, 22 of whom had IRNV visualized on UWF-OCT (37%). On average, patients with IRNV had lower birth weights (BWs) (660.1 vs. 916.8 g, P = 0.001), gestational age (GA) (24.9 vs. 26.1 weeks, P = 0.01), and were more likely to present with ROP in zone I (63.4% vs. 15.8%, P < 0.001). They were also more likely to progress to stage 3 (68.2% vs. 13.2%, P < 0.001) and receive treatment (54.5% vs. 15.8%, P = 0.002). Eyes with IRNV had a higher peak VSS (5.61 vs. 3.73, P < 0.001) and averaged a higher VSS throughout their disease course. On multivariable logistic regression, IRNV was independently associated with progression to stage 3 (P = 0.02) and requiring treatment (P = 0.03), controlling for GA, BW, and initial zone 1 disease.

conclusionsIn this single center study, we found that IRNV occurs in higher risk babies and was an independent risk factor for ROP progression and treatment. These findings may have implications for OCT-based ROP classifications in the future. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Gestational AgeRetinal NeovascularizationRetinopathy of PrematurityTomography, Optical CoherenceCross-Sectional StudiesDisease ProgressionFemaleFollow-Up StudiesFundus OculiHumansInfant, NewbornMalePrognosisRetrospective StudiesIsolated retinal neovascularizationOCTRetinopathy of prematurity

Identifiers

PMID38735640
PMCPMC11446652

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.